ChiCTR2600119274 版本V1.0 版本创建时间2026/02/25 09:50:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600119274 

最近更新日期:

Date of Last Refreshed on:

2026-02-25 09:50:22 

注册时间:

Date of Registration:

2026-02-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

新型手柄式显微镜实时诊断乳房肿块穿刺标本的探索性研究

Public title:

An Exploratory Study on Real-Time Diagnosis of Breast Lump Biopsy Specimens Using a Novel Handheld Microscope

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新型手柄式显微镜实时诊断乳房肿块穿刺标本的探索性研究

Scientific title:

An Exploratory Study on Real-Time Diagnosis of Breast Lump Biopsy Specimens Using a Novel Handheld Microscope

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

储艺平 

研究负责人:

马小鹏 

Applicant:

Chu Yiping 

Study leader:

Ma Xiaopeng  

申请注册联系人电话:

Applicant telephone:

+86 199 7110 5918

研究负责人电话:

Study leader's
telephone:

+86 150 7790 4628

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

chuyiping2024@163.com

研究负责人电子邮件:

Study leader's E-mail:

chuyiping2024@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国安徽省合肥市政务区天鹅湖路1号

研究负责人通讯地址:

中国安徽省合肥市政务区天鹅湖路1号

Applicant address:

1 Swan Lake Road, Zhengwu District, Hefei, Anhui, China

Study leader's address:

1 Swan Lake Road, Zhengwu District, Hefei, Anhui, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国科学技术大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of University of Science and Technology of China

研究负责人所在单位:

中国科学技术大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of University of Science and Technology of China

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026KY伦审第021号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国科学技术大学附属第一医院医学研究伦理委员会

Name of the ethic committee:

Medical Research Ethics Committee of the First Affiliated Hospital of University of Science and Technology of China

伦理委员会批准日期:

Date of approved by ethic committee:

2026-01-26 00:00:00

伦理委员会联系人:

胡怡然

Contact Name of the ethic committee:

Hu Yiran

伦理委员会联系地址:

中国安徽省合肥市庐阳区庐江路17号

Contact Address of the ethic committee:

17 Lujiang Road, Luyang District, Hefei, Anhui, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 551 6228 2931

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国科学技术大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of University of Science and Technology of China

研究实施负责(组长)单位地址:

中国安徽省合肥市政务区天鹅湖路1号

Primary sponsor's address:

1 Swan Lake Road, Zhengwu District, Hefei, Anhui, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

Country:

China

Province:

Anhui

City:

单位(医院):

中国科学技术大学附属第一医院

具体地址:

中国安徽省合肥市政务区天鹅湖路1号

Institution
hospital:

The First Affiliated Hospital of University of Science and Technology of China

Address:

1 Swan Lake Road, Zhengwu District, Hefei, Anhui, China

经费或物资来源:

研究者自筹

Source(s) of funding:

Self-funded by the researchers

研究疾病:

乳房肿块  

Target disease:

Breast lump

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

探索新型手柄式显微镜实时诊断乳房肿块穿刺标本的可行性。以便帮助临床外科医生在彩超引导下空心针穿刺术中快速、准确的探查到肿瘤良恶性情况。  

Objectives of Study:

Exploring the feasibility of a novel handheld microscope for real-time diagnosis of breast lump biopsy specimens. This aims to assist clinical surgeons in rapidly and accurately determining tumour malignancy during ultrasound-guided hollow needle aspiration procedures.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄>18岁; 2. 临床怀疑乳腺癌同意拟行穿刺患者; 3. 受试者自愿签署知情同意书或经伦理委员会审查批准免除签署。

Inclusion criteria

1. Age > 18 years; 2. patients with clinically suspected breast cancer who consent to undergo planned needle biopsy; 3. subjects voluntarily sign an informed consent form or are exempted from signing following review and approval by the ethics committee.

排除标准:

1. 拒绝穿刺或有穿刺禁忌症患者; 2. 既往确诊恶性肿瘤患者; 3. 伴有精神疾病或认知障碍; 4. 依从性较差。

Exclusion criteria:

1. Patients refusing puncture or with contraindications to puncture; 2. patients with a history of confirmed malignancy; 3. those with psychiatric disorders or cognitive impairment; 4. those with poor compliance.

研究实施时间:

Study execute time:

From 2026-02-27 00:00:00 To 2027-01-25 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-27 00:00:00 To 2027-01-25 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

石蜡病理检查

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Paraffin pathological examination

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

ES 的实时诊断结果

Index test:

Real-time diagnostic results of ES

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

临床怀疑乳腺癌同意拟行穿刺患者

例数:

Sample size:

147

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patients with clinically suspected breast cancer who are approved for puncture

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

None

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

 

Country:

China

Province:

Anhui

City:

单位(医院):

中国科学技术大学附属第一医院(安徽省立医院)  

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

ES 的实时诊断结果与石蜡病理诊断结果的总体符合率、敏感性、特异性

指标类型:

主要指标

Outcome:

Overall agreement rate, sensitivity, and specificity between real-time ES diagnosis and paraffin pathological diagnosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不同 BI-RADS 分级的 ES 判读准确性差异

指标类型:

次要指标

Outcome:

Differences in ES interpretation accuracy across different BI-RADS categories

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ES 判读准确率与冰冻快速病理检查准确率的差异

指标类型:

次要指标

Outcome:

Difference in accuracy between ES interpretation and frozen rapid pathological examination

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ES 判读时间与冰冻快速病理检测时间的差异

指标类型:

次要指标

Outcome:

Difference in time between ES interpretation and frozen rapid pathological testing

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ES 引导穿刺组二次穿刺率

指标类型:

附加指标

Outcome:

Re-biopsy rate in the ES-guided biopsy group

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

乳腺穿刺组织

组织:

Sample Name:

Breast tissue biopsy

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 99 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集形式依据批准的病例记录表。 数据管理形式为电子表格

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection is based on the approved case record form. The form of data management is spreadsheet.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-25 09:50:22